Clinical, radiological and B cell count follow up of Egyptian patients with neuromyelitis optica spectrum disorder on rituximab therapy

Clinical, radiological and B cell count follow up of Egyptian patients with neuromyelitis optica spectrum disorder on rituximab therapy

Abstract Background Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen on the surface of B cells and induces cytolysis of B cells. B cells are thought to contribute to myelin damage in neuromyelitis optica spectrum disorder (NMOSD). This study aimed to assess the extent of B cell...

Full description

Saved in:
Bibliographic Details
Main Authors: Janet Masoud, Azza Abdel Nasser, Rasha Mamdouh Saleh, Dina Zamzam, Mohamed M. Fouad, Mohamed A. Abdel Hafeez
Format: Article
Language:English
Published: SpringerOpen 2025-04-01
Series:The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Subjects:
Neuromyelitis optica
Rituximab
CD19
Annualized relapse rate
Extended disability status scale
Online Access:https://doi.org/10.1186/s41983-025-00958-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41983-025-00958-5

Similar Items